The study characterizes the lung cancer tumor microenvironment, linking cellular compositions to immunotherapy resistance and potential therapeutic strategies.
Carolyn Bertozzi-founded Lycia Therapeutics raises $106M to enter the clinic
A different take on protein degradation will enter human trials as Lycia Therapeutics, founded by Nobel laureate Carolyn Bertozzi, has refueled with $106.6 million. The